Morphine activates neuroinflammation in a manner parallel to endotoxin

Opioids create a neuroinflammatory response within the CNS, compromising opioid-induced analgesia and contributing to various unwanted actions. How this occurs is unknown but has been assumed to be via classic opioid receptors. Herein, we provide direct evidence that morphine creates neuroinflammation via the activation of an innate immune receptor and not via classic opioid receptors. We demonstrate that morphine binds to an accessory protein of Toll-like receptor 4 (TLR4), myeloid differentiation protein 2 (MD-2), thereby inducing TLR4 oligomerization and triggering proinflammation. Small-molecule inhibitors, RNA interference, and genetic knockout validate the TLR4/MD-2 complex as a feasible target for beneficially modifying morphine actions. Disrupting TLR4/MD-2 protein–protein association potentiated morphine analgesia in vivo and abolished morphine-induced proinflammation in vitro, the latter demonstrating that morphine-induced proinflammation only depends on TLR4, despite the presence of opioid receptors. These results provide an exciting, nonconventional avenue to improving the clinical efficacy of opioids.

[1]  I. Wilhelm,et al.  Expression and regulation of toll-like receptors in cerebral endothelial cells , 2010, Neurochemistry International.

[2]  T. Kirikae,et al.  Diphosphoryl lipid A derived from the lipopolysaccharide (LPS) of Rhodobacter sphaeroides ATCC 17023 is a potent competitive LPS inhibitor in murine macrophage-like J774.1 cells. , 1994, FEMS immunology and medical microbiology.

[3]  S. Maier,et al.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects , 2010, Brain, Behavior, and Immunity.

[4]  P. Pristovsek,et al.  MD‐2 as the target of curcumin in the inhibition of response to LPS , 2007, Journal of leukocyte biology.

[5]  L. Watkins,et al.  Selection, Preparation, and Evaluation of Small- Molecule Inhibitors of Toll-Like Receptor 4. , 2010, ACS medicinal chemistry letters.

[6]  S. Maier,et al.  Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1β , 2010, Neuroscience.

[7]  K. Rice,et al.  Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors? , 1977, Science.

[8]  S. Akira,et al.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.

[9]  R. Jerala,et al.  MD-2 and Der p 2 — a tale of two cousins or distant relatives? , 2005, Journal of endotoxin research.

[10]  C. Natanson,et al.  Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies , 2011, Expert opinion on drug metabolism & toxicology.

[11]  Hayyoung Lee,et al.  The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.

[12]  Y. Satow,et al.  Crystal Structures of Human MD-2 and Its Complex with Antiendotoxic Lipid IVa , 2007, Science.

[13]  R. Dubner,et al.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia , 1987, Pain.

[14]  L. Watkins,et al.  Pathological and protective roles of glia in chronic pain , 2009, Nature Reviews Neuroscience.

[15]  Kirk W. Johnson,et al.  Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast) , 2009, Brain, Behavior, and Immunity.

[16]  L. Watkins,et al.  A Peptide Antagonist of the TLR4–MD2 Interaction , 2009, Chembiochem : a European journal of chemical biology.

[17]  K. Miyake,et al.  Inhibition of homodimerization of Toll-like receptor 4 by curcumin. , 2006, Biochemical pharmacology.

[18]  L. Watkins,et al.  An MD2 Hot‐Spot‐Mimicking Peptide that Suppresses TLR4‐Mediated Inflammatory Response in vitro and in vivo , 2011, Chembiochem : a European journal of chemical biology.

[19]  M. Narita,et al.  Implication of Activated Astrocytes in the Development of Drug Dependence , 2008, Annals of the New York Academy of Sciences.

[20]  Jon Cohen,et al.  A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis* , 2010, Critical care medicine.

[21]  S. Maier,et al.  Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia , 2008, Brain, Behavior, and Immunity.

[22]  S. Maier,et al.  Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences , 2010, Neuroscience.

[23]  Mark R Hutchinson,et al.  Application of a novel in silico high-throughput screen to identify selective inhibitors for protein-protein interactions. , 2010, Bioorganic & medicinal chemistry letters.

[24]  A. Bytnerowicz,et al.  Air Pollution Distribution Patterns in the San Bernardino Mountains of Southern California: a 40-Year Perspective , 2007, TheScientificWorldJournal.

[25]  Mark R Hutchinson,et al.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. , 2009, Trends in pharmacological sciences.

[26]  Honghong Yao,et al.  Morphine enhances Tat-induced activation in murine microglia , 2009, Journal of NeuroVirology.

[27]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[28]  L. Watkins,et al.  Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains , 2011, Brain, Behavior, and Immunity.

[29]  Kirk W. Johnson,et al.  Opioid-Induced Glial Activation: Mechanisms of Activation and Implications for Opioid Analgesia, Dependence, and Reward , 2007, TheScientificWorldJournal.

[30]  T. Kirkland,et al.  Characterization of monoclonal antibodies to human soluble MD-2 protein. , 2006, Hybridoma.

[31]  S. Maier,et al.  Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia , 2008, Brain, Behavior, and Immunity.

[32]  H. Yin,et al.  Design, synthesis, and evaluation of biotinylated opioid derivatives as novel probes to study opioid pharmacology. , 2008, Bioconjugate chemistry.

[33]  S. Maier,et al.  Exploring the Neuroimmunopharmacology of Opioids: An Integrative Review of Mechanisms of Central Immune Signaling and Their Implications for Opioid Analgesia , 2011, Pharmacological Reviews.

[34]  K. Miyake,et al.  MD-2 Enables Toll-Like Receptor 2 (TLR2)-Mediated Responses to Lipopolysaccharide and Enhances TLR2-Mediated Responses to Gram-Positive and Gram-Negative Bacteria and Their Cell Wall Components1 , 2001, The Journal of Immunology.

[35]  Makiko Kobayashi,et al.  Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. , 2004, International immunology.

[36]  P. Pristovsek,et al.  Taxanes inhibit human TLR4 signaling by binding to MD‐2 , 2008, FEBS letters.

[37]  N. Tsuchimori,et al.  TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules , 2011, Molecular Pharmacology.

[38]  Sangdun Choi,et al.  Similar Structures but Different Roles – An Updated Perspective on TLR Structures , 2011, Front. Physio..